Shots:

• The P-I study involves assessing the safety and PK of AT-527 (550 mg- q2- BID) vs PBO for 5 days in 20 healthy volunteers in a ratio (1:1) to treat COVID-19
• The result showed rapid attainment of steady state levels within 2days of dosing- predicted lung AT-9010 levels were consistently above the EC90 level of 0.5 µM for in vitro inhibition
• AT-527 is an orally administered- direct-acting antiviral agent- currently being evaluated in a P-II study for hospitalized patients with moderate COVID-19 and P-II virology study in patients with mild or mod. COVID-19 in an outpatient setting

 ­ Ref: Atea Pharma | Image: Atea Pharma